ClinicalResearch.com

A new clinical trial of an experimental drug called retatrutide shows it may lead to even greater weight loss than current blockbuster obesity GLP-1 medications. In the study, people with obesity lost an average of more than 25% of their body weight, and some lost substantially more, by targeting three different hormone pathways involved in appetite and metabolism. While side effects like nausea were common, most were manageable, and the results move the injectable drug closer to potential FDA approval. This matters because obesity is linked to diabetes, heart disease, and other serious conditions, and a more powerful treatment could significantly expand options for people who have not had enough success with existing treatments.

Trial of next-gen weight-loss drug retatrutide shows users lose almost a third of their body weight While drugs such as Wegovy target a single gut hormone, retatrutide is among a new class of GLP-1 drugs that aims at three hormone receptors

For most people living with obstructive sleep apnea (OSA), the standard initial treatment is a CPAP machine. These devices are effective, but also uncomfortable, noisy, and hard to use consistently. That’s why new research is generating excitement. A recent clinical trial tested a once-nightly pill designed to address the underlying cause of airway collapse during sleep, and many participants experienced fewer breathing interruptions and improved oxygen levels.

Once-Nightly Pill Targets Airway Collapse to Control Sleep Apnea In a groundbreaking advancement within the field of sleep medicine, researchers have unveiled compelling evidence supporting the efficacy of a novel oral pharmacologic therapy for obstructive sleep

For many cancers, immunotherapy offers hope, but it doesn’t always work. Some tumors can “hide” from the immune system, making treatment less effective. Scientists trying to address this challenge recently found that a common asthma drug, Singulair, may help “switch off” the mechanism tumors use to escape immune attack. In mouse models using tissue from breast, melanoma, ovarian, colon, and prostate cancers, scientists either removed the key tumor pathway or blocked it with the drug. This lead to slower tumor growth and a stronger immune response.

Common asthma drug may turn off tumor 'switch' tied to immunotherapy resistance A drug widely used to treat asthma and allergies may also help fight aggressive cancers, reports a new Northwestern Medicine study that uncovered how tumors hijack common white blood cells to evade immunotherapy.